6:12 PM
 | 
Oct 04, 2007
 |  BC Extra  |  Clinical News

Isis reports hypercholesterolemia data

ISIS said the two higher doses of ISIS 301012 met the primary endpoint of a significant reduction in baseline LDL-C vs. placebo in a Phase II trial to treat familial hypercholesterolemia in...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >